Methamphetamine-associated acute myocardial infarction and cardiogenic shock with normal coronary arteries: Refractory global coronary microvascular spasm

Journal of Invasive Cardiology

Volumn 19, Issue 4, 2007, Pages

  Chen, Jack P ^a  

^a Saint Joseph's Hospital of Atlanta   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; DILTIAZEM; DOPAMINE; ILLICIT DRUG; METHAMPHETAMINE; NITRATE; NITROPRUSSIDE SODIUM; VASODILATOR AGENT;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; ANAMNESIS; ARTICLE; CARDIOGENIC SHOCK; CASE REPORT; CORONARY ARTERY; CORONARY ARTERY SPASM; DRUG DEPENDENCE; DRUG USE; HUMAN; MALE; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION;

ADULT; AMPHETAMINE-RELATED DISORDERS; CENTRAL NERVOUS SYSTEM STIMULANTS; CORONARY ANGIOGRAPHY; CORONARY VASOSPASM; DISEASE PROGRESSION; ELECTROCARDIOGRAPHY; HUMANS; MALE; METHAMPHETAMINE; MYOCARDIAL INFARCTION; SHOCK, CARDIOGENIC;

EID: 34147102162     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. http://www.usdoj.gov/dea/concern/meth.htm.
2. Office of Applied Studies: Summary of findings from the 2000 national household survey on drug abuse. DHHS Publication No. NHSDA Series H-13, (SMA) 01-3549. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2001.
3. Miller MA. History and epidemiology of amphetamine abuse in the United States. In: Klee H (Ed). Amphetamine Misuse. International Perspectives on Current Trends. Amsterdam: Harwood Academic Publishers, 1997.
4. Turnipseed SD, Richards JR, Kirk JD, et al. Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after methamphetamine use. J Emerg Med 2003;24:369-372.
5. Wijetunga M, Bhan R, Lindsay J. Acute coronary syndrome and crystal methamphetamine use: A case series. Hawaii Med J 2004;63:8-13.
6. Yoshida T. Use and misuse of amphetamines: An international overview. In: Klee H (ed). Amphetamine Misuse: International Perspectives on Current Trends. Amsterdam: Harwood Academic Publishers. 1997, pp. 1-18.
7. Helschober B, Derlet RW. Update on amphetamine abuse. West J Med 1989;151:70-71.
8. Hardman JG, Limbird LE (Eds). Goodman and Gilman's the Pharmacological Basis of Therapeutics. New York: McGraw-Hill Companies; 1996.
9. Morgan P, Beck JE. The legacy and the paradox: Hidden contexts of methamphetamine use in the United States. In: Klee H (Ed). Amphetamine Misuse: International Perspectives on Current Trends. Amsterdam: Hardwood Publishers; 1997, pp. 135-162.
10. MaulikN, Engelman RM, Wei Z, et al. Drug-induced heat-shock preconditioning improves postischemic ventricular recovery after cardiopulmonary bypass. Circulation 1995;92:1381-1388.
11. Nestor TA, Tamamoto WI, Kam TH, Schultz T. Crystal methamphetamine- induced acute pulmonary edema. A case report. Hawaii Med J 1989;48:457-460.
12. Hong R, Matsuyama E, Nur K. Cardiomyopathy associated with the smoking of crystal methamphetamine. JAMA 1991;26:1152-1154.
13. Schaiberger PH, Kennedy TC, Miller FC, et al. Pulmonary hypertension associated with long-term inhalation of "crank" methamphetamine. Chest 1993;104:614-616.
14. Kontos MC, Schmidt KL, Nicholson CS, et al. Myocardial perfusion imaging with technetium-99 sestamibi in patients with cocaine-associated chest pain. Ann Emerg Med 1999;33:639-645.
15. Carson P, Oldroyd K, Phadke K. Myocardial infarction due to amphetamine. Br Med J 1987;294:1525-1526.
16. Packe GE, Garton MJ, Jennings K. Acute myocardial infarction caused by intravenous amphetamine abuse. Br Heart J 190;64:23-24.
17. Furst SR, Fallon SP, Reznik GN, Shah PK. Myocardial infarction after inhalation of methamphetamine. N Eng J Med 1990;323:1147-1148.
18. Ragaland AS, Ismail Y, Arsura EL. Myocardial infarction after amphetamine use. Am Heart J 1993;125:247-9.
19. Karch SB, Stephens BG, Ho C-H. Methamphetamine-related deaths in San Francisco: Demographic, pathologic, ad toxicologic profiles. J Forensic Sci 1999;44:359-368.
20. Morris DC. Acute myocardial infarction temporally related to cocaine use, clinical, angiographic, and pathophysiologic observations. Ann Intern Med 1987;107:13-18.
21. Hollander JE, Hoffman RS. Cocaine-induced myocardial infarction: An analysis and review of the literature. J Emerg Med 1992;10:169-177.
22. Stenberg RG, Winniford MD, Hillis LD, et al. Simultaneous acute thrombosis of two major coronary arteries following intravenous cocaine use. Arch Pathol Lab Med 1989;113:521-524.
23. Tazelaar HD, Karch SB, Stephens BG, Billingham ME. Cocaine and the heart. Hum Pathol 1987;18:195-199.
24. Wilson L. Rapid progression of coronary artery disease in the setting of chronic cocaine abuse. J Emerg Med 1998;16:631-634.
25. Larsson PT, Hjemdahl P, Olsson G, et al. Platelet aggregability in humans: Contrasting in vivo and in vitro findings during sympathy-adrenal activation and relationship to serum lipids. Eur J Clin Invest 1990;20:398-405.
26. O'Brien JR, Salmon GP. Shear stress activation of platelet glycoprotein IIB/IIa plus von Willebrand factor causes aggregation: Filter blockage and the long bleeding time in von Willebrand's disease. Blood 1987;70:1354-1361.
27. van't Hof A, Liem A, Suryapranata H, et al. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute MI. Myocardial blush grade. Circulation 1998;97:2302-2306.
28. Abbo K, Dooris M, Glazier S, et al. Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol 1995;75:778-782.
29. Ito H, Tomooka T, Sakai N, et al. Lack of myocardial perfusion immediately after successful thrombolysis: Predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation 1996;93:223-228.
30. Gibson M, Cannon C, Murphy S, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000;101:125-130.
31. Stone GW, Webb JG, Cox D, et al. Primary angioplasty in acute myocardial infarction with distal protection of the mirocirculation: Principal results from the prospective, randomized EMERALD trial. J Am Coll Cardiol 2004;43:285A.
32. Baim DS, Wahr D, George B, et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aortocoronary bypass grafts. Circulation 2002;105:1285-1290.
33. Stone GW, Cox DA, Low R, et al. Safety and efficacy of a novel device for treatment of thrombotic and atherosclerotic lesions in native coronary arteries and saphenous vein grafts. Results from the multicenter X-sizer for treatment of thrombus and atherosclerosis in coronary applications trial (X-TRACT) study. Catheter Cardiovasc Interv 2003;58:419-427.
34. Silva JA, Ramee SR, Cohen D, et al. Rheolytic thrombectomy for the treatment of acute myocardial infarction in patients with angiographic large thrombus burden: One-year results of the VeGAS 2 acute myocardial infarction registry. J Am Coll Cardiol 2004;43:248A.
35. Hendler A, Aronovich A, Kaluski E, et al. Optimization of myocardial perfusion after primary coronary angioplasty following an acute myocardial infarction. Beyond TIMI 3 flow. J Invasive Cardiol 2006;18:32-36.
36. Fischell TA, Carter AJ, Foster MT, et al. Reversal of non-reflow during vein graft stenting using high velocities boluses of intracoronary adenosine. Cathet Cardiovasc Diagn 1998;45:360-365.
37. Yoshiashi T, Hiroshi I, Katsuomi I, et al. Beneficial effects of intracoronary verapamil on microvascular and myocardial damage in patients with acute myocardial infarction. Circ Res 2001;37:347-351.
38. Chen JP. Dual lumen catheters: More than just aspiration. J Invasive Cardiol 2006;18:346.
39. Rawitscher D, Levin T, Cohen I, et al. Rapid reversal of non-reflow using abciximab after coronary intervention. Cathet Cardiovasc Diagn 1997;42:187-190.